APA (7th ed.) Citation

NA, P., A, C., I, U., J, v. K., HJ, B., JM, v. D., . . . O, K. (2022). Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study. Frontiers in oncology, 12, 969855. https://doi.org/10.3389/fonc.2022.969855

Chicago Style (17th ed.) Citation

NA, Peters, et al. "Consensus Molecular Subtype 4 (CMS4)-targeted Therapy in Primary Colon Cancer: A Proof-of-concept Study." Frontiers in Oncology 12 (2022): 969855. https://doi.org/10.3389/fonc.2022.969855.

MLA (9th ed.) Citation

NA, Peters, et al. "Consensus Molecular Subtype 4 (CMS4)-targeted Therapy in Primary Colon Cancer: A Proof-of-concept Study." Frontiers in Oncology, vol. 12, 2022, p. 969855, https://doi.org/10.3389/fonc.2022.969855.